Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 1 (January 1), 2008: pp. 44-53
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.3787

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Laurentiis, M.
Right arrow Articles by De Placido, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Laurentiis, M.
Right arrow Articles by De Placido, S.
Related Articles
Right arrowRelated Correspondence

Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials

Michele De Laurentiis, Giuseppe Cancello, Diego D'Agostino, Mario Giuliano, Antonio Giordano, Emilia Montagna, Rossella Lauria, Valeria Forestieri, Angela Esposito, Lucrezia Silvestro, Roberta Pennacchio, Carmen Criscitiello, Agnese Montanino, Gennaro Limite, Angelo Raffaele Bianco, Sabino De Placido

From the Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università di Napoli "Federico II"; Dipartimento di Chirurgia Generale, Oncologica e Videoassistita, Università di Napoli "Federico II", Napoli, Italy

Corresponding author: Michele De Laurentiis, MD, PhD, Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università "Federico II", via Sergio Pansini, 5, 80131, Napoli, Italy; e-mail: delauren{at}unina.it; e-mail: michele.delaurentiis{at}unina.it

Purpose: We conducted a meta-analysis of randomized trials that evaluated the efficacy of incorporating taxanes into anthracycline-based regimens for early breast cancer (EBC). We aimed to determine whether this approach improves disease-free survival (DFS) and overall survival (OS) and whether benefits are maintained across relevant patient subgroups.

Methods: Studies were retrieved by searching the PubMed database and the proceedings of major conferences. We extracted hazard ratios (HR) and 95% CIs for DFS and OS from each trial and obtained pooled estimates using an inverse-variance model.

Results: Thirteen studies were included in the meta-analysis (N = 22,903 patients). The pooled HR estimate was 0.83 (95% CI, 0.79 to 0.87; P < .00001) for DFS and 0.85 (95% CI, 0.79 to 0.91; P < .00001) for OS. Risk reduction was not influenced by the type of taxane, by estrogen receptor (ER) expression, by the number of axillary metastases (N1 to 3 v N4+), or by the patient's age/menopausal status. Sensitivity analysis showed that taxanes given in combination with anthracyclines, unlike sequential administration, did not significantly improve OS. However, the test for interaction showed that HR did not differ between the two schedules (P = .54). Taxane administration resulted in an absolute 5-year risk reduction of 5% for DFS and 3% for OS.

Conclusion: The addition of a taxane to an anthracycline-based regimen improves the DFS and OS of high-risk EBC patients. The DFS benefit was independent of ER expression, degree of nodal involvement, type of taxane, age/menopausal status of patient, and administration schedule.

Supported by Grant No. 1044: AIRC (Associazione Italiana Ricerca sul Cancro) regional grant.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • Selection of a Taxane As Well As Anthracycline for Early Breast Cancer
    Peter H. Graham
    JCO 2008 26: 2416-2417 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
L. J. Goldstein, A. O'Neill, J. A. Sparano, E. A. Perez, L. N. Shulman, S. Martino, and N. E. Davidson
Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197
J. Clin. Oncol., September 1, 2008; 26(25): 4092 - 4099.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
N. C Turner and A. L Jones
Management of breast cancer--Part II
BMJ, July 11, 2008; 337(jul11_2): a540 - a540.
[Full Text]


Home page
JCOHome page
M. De Laurentiis and S. De Placido
In Reply
J. Clin. Oncol., May 10, 2008; 26(14): 2417 - 2417.
[Full Text] [PDF]


Home page
JCOHome page
P. H. Graham
Selection of a Taxane As Well As Anthracycline for Early Breast Cancer
J. Clin. Oncol., May 10, 2008; 26(14): 2416 - 2417.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online